chr17-47946670-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PS1_ModeratePM1PM2PP3_StrongPP5_Very_Strong
The NM_018129.4(PNPO):c.674G>A(p.Arg225His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000273 in 1,614,186 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 11/19 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely pathogenicin UniProt.
Frequency
Consequence
NM_018129.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PNPO | NM_018129.4 | c.674G>A | p.Arg225His | missense_variant | 7/7 | ENST00000642017.2 | NP_060599.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PNPO | ENST00000642017.2 | c.674G>A | p.Arg225His | missense_variant | 7/7 | NM_018129.4 | ENSP00000493302 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000328 AC: 5AN: 152212Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251436Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135890
GnomAD4 exome AF: 0.0000267 AC: 39AN: 1461856Hom.: 0 Cov.: 32 AF XY: 0.0000344 AC XY: 25AN XY: 727242
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152330Hom.: 0 Cov.: 32 AF XY: 0.0000403 AC XY: 3AN XY: 74490
ClinVar
Submissions by phenotype
Pyridoxal phosphate-responsive seizures Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Génétique des Maladies du Développement, Hospices Civils de Lyon | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2016 | This variant was classified as: Pathogenic. This variant was detected in homozygous state. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jul 03, 2019 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 09, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Nov 16, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 16, 2023 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 225 of the PNPO protein (p.Arg225His). This variant is present in population databases (rs550423482, gnomAD 0.007%). This missense change has been observed in individual(s) with pyridoxine-responsive epilepsy or neonatal onset epilepsy (PMID: 24266778, 24645144, 24658933, 24781210, 25762494). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 223153). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PNPO protein function. Experimental studies have shown that this missense change affects PNPO function (PMID: 24645144, 24658933). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2022 | PNPO: PM3:Strong, PM1, PM2, PS3:Moderate - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 01, 2019 | Published functional studies have shown that R225H significantly reduces expression of PNPO activity (Mills et al., 2014; Levtova et al., 2015); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 31589614, 31623504, 31397616, 29286531, 28832562, 29453417, 27864847, 24645144, 26535729, 25601884, 24781210, 27342130, 26938784, 24658933, 25762494, 24266778) - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | May 27, 2022 | - - |
Fetal growth restriction;C0036572:Seizure;C0456070:Growth delay Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 27, 2016 | - - |
Neuronopathy, distal hereditary motor, type 5A Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Oct 08, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at